Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 14, 2015, Pages 4453-4458

  Harbut, Michael B ^a   Vilchèze, Catherine ^b   Luo, Xiaozhou ^c   Hensler, Mary E ^d   Guo, Hui ^a   Yang, Baiyuan ^a   Chatterjee, Arnab K ^a   Nizet, Victor ^d   Jacobs, William R ^b   Schultz, Peter G ^a,c   Wang, Feng ^a  

^a California Institute for Biomedical Research   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Auranofin; Gram positive; MRSA; Tuberculosis

Indexed keywords

AURANOFIN; DIAMIDE; PARAQUAT; THIOL; THIOREDOXIN REDUCTASE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; GLUTATHIONE; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACILLUS SUBTILIS; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; HOMEOSTASIS; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENE DELETION; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM TUBERCULOSIS; OXIDATION REDUCTION REACTION; STEM CELL;

BACILLUS SUBTILIS; BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MURINAE; MYCOBACTERIUM TUBERCULOSIS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; AURANOFIN; BACILLUS SUBTILIS; BACTERIAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS FAECIUM; FEMALE; GENE DELETION; GLUTATHIONE; HOMEOSTASIS; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXIDATION-REDUCTION; OXIDATIVE STRESS; STAPHYLOCOCCUS AUREUS; STEM CELLS; SULFHYDRYL COMPOUNDS; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84928920149     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1504022112     Document Type: Article

References (53)

1. Boucher HW, et al. (2009) Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1):1-12.
2. Arias CA, Murray BE (2009) Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 360(5):439-443.
3. Klevens RM, et al.; Active Bacterial Core surveillance (ABCs) MRSA Investigators (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15):1763-1771.
4. Abubakar I, et al. (2013) Drug-resistant tuberculosis: Time for visionary political leadership. Lancet Infect Dis 13(6):529-539.
5. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K (2011) The challenge of new drug discovery for tuberculosis. Nature 469(7331):483-490.
6. Stewart GR, Robertson BD, Young DB (2003) Tuberculosis: A problem with persistence. Nat Rev Microbiol 1(2):97-105.
7. Sacchettini JC, Rubin EJ, Freundlich JS (2008) Drugs versus bugs: In pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol 6(1):41-52.
8. Kohanski MA, Dwyer DJ, Collins JJ (2010) How antibiotics kill bacteria: From targets to networks. Nat Rev Microbiol 8(6):423-435.
9. Ritz D, Beckwith J (2001) Roles of thiol-redox pathways in bacteria. Annu Rev Microbiol 55:21-48.
10. Lu J, Holmgren A (2014) The thioredoxin antioxidant system. Free Radic Biol Med 66: 75-87.
11. Lundström J, Holmgren A (1990) Protein disulfide-isomerase is a substrate for thioredoxin reductase and has thioredoxin-like activity. J Biol Chem 265(16):9114-9120.
12. Holmgren A, Sengupta R (2010) The use of thiols by ribonucleotide reductase. Free Radic Biol Med 49(11):1617-1628.
13. Prinz WA, Aslund F, Holmgren A, Beckwith J (1997) The role of the thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in the Escherichia coli cytoplasm. J Biol Chem 272(25):15661-15667.
14. Newton GL, et al. (1996) Distribution of thiols in microorganisms: Mycothiol is a major thiol in most actinomycetes. J Bacteriol 178(7):1990-1995.
15. Fahey RC, Brown WC, Adams WB, Worsham MB (1978) Occurrence of glutathione in bacteria. J Bacteriol 133(3):1126-1129.
16. Tomb JF, et al. (1997) The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388(6642):539-547.
17. Uziel O, Borovok I, Schreiber R, Cohen G, Aharonowitz Y (2004) Transcriptional regulation of the Staphylococcus aureus thioredoxin and thioredoxin reductase genes in response to oxygen and disulfide stress. J Bacteriol 186(2):326-334.
18. Scharf C, et al. (1998) Thioredoxin is an essential protein induced by multiple stresses in Bacillus subtilis. J Bacteriol 180(7):1869-1877.
19. Andreu N, et al. (2010) Optimisation of bioluminescent reporters for use with mycobacteria. PLoS ONE 5(5):e10777.
20. Loebel RO, Shorr E, Richardson HB (1933) The influence of foodstuffs upon the respiratory metabolism and growth of human tubercle bacilli. J Bacteriol 26(2):139-166.
21. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43(3):717-731.
22. Finkelstein AE, et al. (1976) Auranofin: New oral gold compound for treatment of rheumatoid arthritis. Ann Rheum Dis 35(3):251-257.
23. Zumla AI, et al. (2014) New antituberculosis drugs, regimens, and adjunct therapies: Needs, advances, and future prospects. Lancet Infect Dis 14(4):327-340.
24. Cassetta MI, Marzo T, Fallani S, Novelli A, Messori L (2014) Drug repositioning: Auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals 27(4):787-791.
25. Hokai Y, et al. (2014) Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains. J Inorg Biochem 138:81-88.
26. Angelucci F, et al. (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: Structural and kinetic aspects. J Biol Chem 284(42):28977-28985.
27. Jeon KI, Byun MS, Jue DM (2003) Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med 35(2):61-66.
28. Gromer S, Arscott LD, Williams CH, Jr, Schirmer RH, Becker K (1998) Human placenta thioredoxin reductase: Isolation of the selenoenzyme, steady-state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273(32):20096-20101.
29. Tejman-Yarden N, et al. (2013) A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother 57(5): 2029-2035.
30. Kuntz AN, et al. (2007) Thioredoxin glutathione reductase from Schistosoma mansoni: An essential parasite enzyme and a key drug target. PLoS Med 4(6):e206.
31. Fahey RC (2013) Glutathione analogs in prokaryotes. Biochim Biophys Acta 1830(5): 3182-3198.
32. Vilchèze C, et al. (2008) Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol Microbiol 69(5):1316-1329.
33. Posada AC, et al. (2014) Importance of bacillithiol in the oxidative stress response of Staphylococcus aureus. Infect Immun 82(1):316-332.
34. Gaballa A, et al. (2010) Biosynthesis and functions of bacillithiol, a major low-molecularweight thiol in Bacilli. Proc Natl Acad Sci USA 107(14):6482-6486.
35. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high-density mutagenesis. Mol Microbiol 48(1):77-84.
36. Griffin JE, et al. (2011) High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog 7(9):e1002251.
37. Jain P, et al. (2014) Specialized transduction designed for precise high-throughput unmarked deletions in Mycobacterium tuberculosis. MBio 5(3):e01245-14.
38. Arscott LD, Gromer S, Schirmer RH, Becker K, Williams CH, Jr (1997) The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc Natl Acad Sci USA 94(8): 3621-3626.
39. Akif M, Khare G, Tyagi AK, Mande SC, Sardesai AA (2008) Functional studies of multiple thioredoxins from Mycobacterium tuberculosis. J Bacteriol 190(21): 7087-7095.
40. Moore EC, Reichard P, Thelander L (1964) Enzymatic synthesis of deoxyribonucleotides, V: Purification and properties of thioredoxin reductase from Escherichia coli B. J Biol Chem 239:3445-3452.
41. Mishra S, Imlay J (2012) Why do bacteria use so many enzymes to scavenge hydrogen peroxide? Arch Biochem Biophys 525(2):145-160.
42. Jaeger T, et al. (2004) Multiple thioredoxin-mediated routes to detoxify hydroperoxides in Mycobacterium tuberculosis. Arch Biochem Biophys 423(1):182-191.
43. Ilari A, et al. (2012) A gold-containing drug against parasitic polyamine metabolism: The X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino Acids 42(2-3): 803-811.
44. Engst S, Miller SM (1999) Alternative routes for entry of HgX2 into the active site of mercuric ion reductase depend on the nature of the X ligands. Biochemistry 38(12): 3519-3529.
45. Chircorian A, Barrios AM (2004) Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: A possible mechanism for the antiarthritic activity of Au(I). Bioorg Med Chem Lett 14(20):5113-5116.
46. Krishnamurthy D, et al. (2008) Gold(I)-mediated inhibition of protein tyrosine phosphatases: A detailed in vitro and cellular study. J Med Chem 51(15):4790-4795.
47. Patel MP, Blanchard JS (1999) Expression, purification, and characterization of Mycobacterium tuberculosis mycothione reductase. Biochemistry 38(36):11827-11833.
48. Madeira JM, Gibson DL, Kean WF, Klegeris A (2012) The biological activity of auranofin: Implications for novel treatment of diseases. Inflammopharmacology 20(6):297-306.
49. Kean WF, Hart L, Buchanan WW (1997) Auranofin. Br J Rheumatol 36(5):560-572.
50. Suarez-Almazor ME, Spooner CH, Belseck E, Shea B (2000) Auranofin versus placebo in rheumatoid arthritis. Cochrane Database Syst Rev (2):CD002048.
51. Blodgett RC, Jr, Pietrusko RG (1986) Long-term efficacy and safety of auranofin: A review of clinical experience. Scand J Rheumatol Suppl 63:67-78.
52. Basaraba RJ (2008) Experimental tuberculosis: The role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb) 88(Suppl 1):S35-S47.
53. Hensler ME, et al. (2014) Anthracimycin activity against contemporary methicillinresistant Staphylococcus aureus. J Antibiot (Tokyo) 67(8):549-553.